Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
9090 Ergebnisse für "tolerated s" unter Somagenetix
Benralizumab in Eosinophilic Granulomatosis with Polyangiitis compl...
... as primarily infective. Active EGPA with cardiac and CNS involvement complicated by a secondary S ... therapy was combined with Benralizumab, which was well tolerated and EGPA resolved rapidly. Benralizumab ... s ... infective. Active EGPA with cardiac and CNS involvement complicated by a secondary S. aureus sepsis was ... s ...
The effect of S-adenosylmethionine on self-mutilation in a patient ...
... effect of S-adenosylmethionine (SAM) on the neurological symptoms, which motivated us to evaluate this ... tolerated, a total of 1,762 events of self-mutilation were recorded, of which 1,281 events were in the ... The effect of S-adenosylmethionine on self-mutilation in a patient with Lesch-Nyhan disease ... The effect of S-adenosylmethionine on self-mutilation in a patient with Lesch-Nyhan disease ... The effect of S-adenosylmethionine on self-mutilation in a patient with Lesch-Nyhan disease ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
8336 Ergebnisse für "tolerated s" unter University of Zurich
Correction of metabolic acidosis with potassium citrate in renal tr...
... transplant patients with metabolic acidosis ( S-[HCO(3)(-)] <24 mmol/L) undergoing treatment with either ... potassium citrate to maintain S-[HCO(3)(-)] >24 mmol/L, or potassium chloride (control group). Iliac crest ... included 30 renal transplant patients with metabolic acidosis ( S-[HCO(3)(-)] <24 mmol/L) undergoing ... treatment with either potassium citrate to maintain S-[HCO(3)(-)] >24 mmol/L, or potassium chloride (control ...
Successful treatment of SAPHO syndrome with apremilast - Zurich Ope...
... improve symptoms. Therapy with etanercept was not tolerated, and due to a previous demyelinating ... tolerated, and due to a previous demyelinating peripheral neuropathy, further treatment with TNF inhibitors ... syndrome with apremilast Adamo, S ; Nilsson, J ; Krebs, A ; Steiner, U ; Cozzio, A ; French, L E ; Kolios ... tolerated, and due to a previous demyelinating peripheral neuropathy, further treatment with TNF inhibitors ...
CSL Vifor
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor
8952 Schlieren, Zürcherstrasse 39D
+41 58 851 80 00
Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.
CSL Vifor
Zürcherstrasse 39D
8952 Schlieren
85 Ergebnisse für "tolerated s" unter CSL Vifor
News Releases | CSL
... through 108 weeks of treatment Sparsentan was well- tolerated with a consistent safety profile across all ... - tolerated and has shown a comparable safety profile to irbesartan. "This is a preliminary data picture from ... emissions by 2030. Learn About Our Targets Along with our sustainability strategy, CSL’ s community ... proteinuria that was sustained through 108 weeks of treatment Sparsentan was well- tolerated with a consistent ...
News Releases | CSL
... , randomized multicenter study showed that Ferinject® is an effective and well- tolerated alternative to iron ... . Last accessed: June 2018. Hercberg S, et al. Iron deficiency in Europe. Public Health Nutr. 2007;4(2b ... emissions by 2030. Learn About Our Targets Along with our sustainability strategy, CSL’ s community ... an effective and well- tolerated alternative to iron sucrose for the treatment of iron deficiency ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
5407 Ergebnisse für "tolerated s" unter ETH Entrepreneurship
S: j_jnNORPIEProceeding_indledning.PDF
... S: j_jnNORPIEProceeding_indledning.PDF A Novel Concept for Transformer Volt Second Balancing of a ... D − − = (2) uΔ K(z) GH0 uT,1 + im,m + - i =0m,ref T T +uΔ TTD Sensor 1+sT1 1 sT 1 Reset sLH 1 S/H S ... S: j_jnNORPIEProceeding_indledning.PDF ... S: j_jnNORPIEProceeding_indledning.PDF A Novel Concept for Transformer Volt Second Balancing of a ... S: j_jnNORPIEProceeding_indledning.PDF ...
A/S website
... Welcome to the A/ S Research Group The Chair of Architecture and Building Systems (A/ S) is an ... Gebäudesysteme (A/ S) ist ein interdisziplinäres Forscherteam, das aktive und passive Systeme der ... A/ S website ... A/ S website 0 Skip to Content Team – view all – Arno Schlueter Marco Baur Krishna Bharathi Esther ... A/ S website ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
1766 Ergebnisse für "tolerated s" unter University Hospital Zurich, Research and Education Office
... - tolerated treatment strategies for these diseases. OVERVIEW In our clinic, we treat women that have ... adenocarcinoma. Anugraham M, Jacob F, Everest-Dass AV, Schoetzau A, Nixdorf S, Hacker NF, Fink D, Heinzelmann ... - tolerated treatment strategies for these diseases. OVERVIEW In our clinic, we treat women that have ... adenocarcinoma. Anugraham M, Jacob F, Everest-Dass AV, Schoetzau A, Nixdorf S, Hacker NF, Fink D, Heinzelmann ...
... to explore how such insights can be translated towards more effective and better- tolerated anti ... SE, Shorrocks AK, de Marco Zompit M, Day M, Blaauwendraad J, Bundschuh D, Bonham S, Fischer R, Fink D ... to explore how such insights can be translated towards more effective and better- tolerated anti ... SE, Shorrocks AK, de Marco Zompit M, Day M, Blaauwendraad J, Bundschuh D, Bonham S, Fischer R, Fink D ...
Bio-Technopark Schlieren-Zürich
8952 Schlieren, Wagistrasse 23
+41 76 336 99 44
mario.jenni@bio-technopark.ch
The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.
Bio-Technopark Schlieren-Zürich
Wagistrasse 23
8952 Schlieren
55 Ergebnisse für "tolerated s" unter Bio-Technopark Schlieren-Zürich
Molecular Partners Provides Update from ACTIV-3 Global Clinical Stu...
... randomized in the ensovibep arm of the study. Ensovibep was observed to be generally safe and well tolerated ... ’ infectious disease pipeline. As a DARPin therapeutic candidate, it is designed to target SARS-CoV-2’ s spike ... observed to be generally safe and well tolerated with reported side effects consistent with standard of ... candidate, it is designed to target SARS-CoV-2’ s spike protein at three sites to limit viral escape via ...
Interim Management Statement Q1 2023 of Molecular Partners: Well Ca...
... localized CD40 activation provided by MP0317. The candidate was also seen to be safe and well tolerated ... . Humanized mouse models confirmed MP0533’ s ability to activate intra-tumoral T-cells and control tumor growth ... CD40 activation provided by MP0317. The candidate was also seen to be safe and well tolerated. MP0317 ... . Humanized mouse models confirmed MP0533’ s ability to activate intra-tumoral T-cells and control tumor growth ...
Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
1642 Ergebnisse für "tolerated s" unter Roche Glycart AG
cobas s 201 System
... . cobas s 201 system The cobas s 201 system is a complete NAT solution supporting the central needs of ... from infectious diseases with modular NAT screening The cobas s 201 system is a complete nucleic acid ... cobas s 201 System ... https://diagnostics.roche.com/global/en/products/systems/cobas- s-201-system.html ... cobas s 201 System ...
cobas s 201 System
... . Protect patients from infectious diseases with modular NAT screening The cobas s 201 system is a complete ... technology and modular automation, the cobas s 201 system minimizes hands-on time across the entire testing ... cobas s 201 System ... https://diagnostics.roche.com/nl/en/products/systems/cobas- s-201-system.html ... cobas s 201 System ...
InCephalo AG
8952 Schlieren, Wagistrasse 21
InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.
InCephalo AG
Wagistrasse 21
8952 Schlieren
1 Ergebnisse für "tolerated s" unter InCephalo AG
InCephalo Therapeutics
... Nevertheless, one of the biggest challenges for IL-12 treatments is that it is poorly tolerated in the blood of ... Cephalo ‘ s Compartment Lock technology, also called C- Lock , allows tailor-made molecules for local ... molecules for local application of drugs behind the blood brain barrier. In Cephalo ’ s drug discovery team ...
Standortförderung Kanton Zürich
https://www.zh.ch/de/volkswirtschaftsdirektion/amt-fuer-wirtschaft/standortfoerderung.html
8090 Zürich, Walchestrasse 19
+41 43 259 49 92
standort@vd.zh.ch
The Division of Business and Economic Development supports resident companies, promotes Zurich's innovation capacity by way of connecting the relevant stakeholders in key industries, fosters external economic relations and offers guidance to companies interested in moving to Zurich.
Standortförderung Kanton Zürich
Walchestrasse 19
8090 Zürich
1401 Ergebnisse für "tolerated s" unter Standortförderung Kanton Zürich
Ratingbericht S&P Global Ratings 2023
... Ratingbericht S&P Global Ratings 2023 Canton of Zurich November 20, 2023 This report does not ... www.spglobal.com/ratingsdirect November 20, 2023 1 S&P Global Ratings believes that very strong financial ... Ratingbericht S&P Global Ratings 2023 ... Ratingbericht S&P Global Ratings 2023 Canton of Zurich November 20, 2023 This report does not ... Ratingbericht S&P Global Ratings 2023 ...
Arbeitsbewilligung für angestellte Person mit Schutzstatus S beantr...
... zurücksetzen Suche Schliessen Arbeitsbewilligung für angestellte Person mit Schutzstatus S beantragen Wichtige ... : Voraussetzungen Vorteile: Benötigte Unterlagen Vorteile: Nachweis Schutzstatus S; Kopie des Ausländerausweises ... Arbeitsbewilligung für angestellte Person mit Schutzstatus S beantragen | Kanton Zürich ... Arbeitsbewilligung für angestellte Person mit Schutzstatus S beantragen | Kanton Zürich Navigation ... Arbeitsbewilligung für angestellte Person mit Schutzstatus S beantragen | Kanton Zürich ...
Kowa Pharmaceutical Europe AG
https://kowapharmaceuticals.eu/
8952 Schlieren, Zürcherstrasse 39D
Kowa Pharmaceutical Europe Co. Ltd. is a specialty pharmaceutical company located in the UK and is a division of Kowa Company, Ltd., a multinational Japanese company actively engaged in a broad variety of manufacturing and trading activities. Kowa are committed to improving health standards in Europe and globally.
Kowa Pharmaceutical Europe AG
Zürcherstrasse 39D
8952 Schlieren
5 Ergebnisse für "tolerated s" unter Kowa Pharmaceutical Europe AG
... pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined ... . Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, et al. High-Dose Versus Low-Dose Pitavastatin ... pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined ... . Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, et al. High-Dose Versus Low-Dose Pitavastatin ...
Kowa corporate
... New Drug Research Laboratories and Fuji Laboratory are the core centres for Kowa Company Ltd.’ s ... the core centres for Kowa Company Ltd.’ s research and development activities in Japan and globally. In ...